Olympic Track Star Gabby Thomas Jokes She’s a ‘Hater’ of Ozempic: ‘I Think About Food All Day’

News Room By News Room
3 Min Read

Gabby Thomas is sharing the hilariously relatable reason she’s not a fan of Ozempic.

On March 21, the 28-year-old track star, who took home three gold medals at the 2024 Paris Summer Games, posted a TikTok video and joked about being a “hater” of those taking the trendy weight-loss aid.

Ozempic is an FDA-approved prescription medication to treat type 2 diabetes. The medication — taken weekly by injection in the thigh, stomach or arm — is a brand name for semaglutide, which works in the brain to impact satiety. 

The drug has gained popularity in and out of Hollywood over the last few years as many people turn to it for weight loss, even when not medically necessary. 

“No shade, but the girls on Ozempics are really starting to piss me off,” she teased. “You mean to tell me, I’m fighting the physical urge to run over to Dairy Queen and get a Blizzard. Meanwhile, they’re not even thinking about food? I think about food all day.”

Never miss a story — sign up for PEOPLE’s free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. 

“Don’t get me wrong, I’m not anti-Ozmempics. I, too, tried to be on the Ozempics. I filled out a form and everything and they said, ‘Gabby, no.’ So now I’m a hater. I am, in fact, a hater…unless you can get me on the Ozempics,” the athlete quipped, before whispering, “If you can get me on the Ozempics, DM me.”

“I’m jk……kind of 😂😂😂” she added in the caption.

In the comments section, fans of Thomas laughed at the clip and praised her relatability.

“The fact that a whole Olympian is fighting food noise like the rest of us. Ily for this🫶🏾” one person wrote, while another added, “This is too real Gabby.”

“ ‘THEE OZEMPICS’ 😂😂😂 If anyone can go get a blizzard it’s you.🤣” one user said.

WNBA star Cameron Brink also commented, “I’m crying gabby 🤣🤣🤣

Read the full article here

TAGGED:
Share This Article
Leave a comment